Maraganore wins best biopharma CEO vote; Vounatsos tops worst list
STAT readers have once again crowned the best and worst biopharma CEOs of the year — and it’s an all-Cambridge, Mass., pairing.
Related Articles
How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma
“Bringing control of drug development, clinical trials, and manufacturing fully back to the United States requires substantial financial investments,” writes MassBio CEO Kendalle Burlin O’Connell.
Apple will offer millions of AirPod users a hearing aid. Can it convince them to use it?
AirPods Pro earbuds will soon double as hearing aids for people with mild to moderate hearing loss.
Why so many patients are confused about CPR and do-not-resuscitate orders
Doctors assume patients want CPR, but many don’t know how to ask about it. There’s a reason why.
How a government scientist is pushing to supersize research into ultra-processed foods
Kevin Hall’s research at the NIH presents an existential challenge to the food industry, but he’s asking the food industry to work with him.
Trump admits he still doesn’t have an Affordable Care Act replacement plan
Trump’s attacks on the popular policy create more uncertainty for his party and for the health care industry.
Five takeaways from Congress’ hearing on overhauling organ transplant system
A year after a big shakeup in the management of the organ transplant network, stories of mismanagement and sloppiness remain common.
Los Angeles County: the epicenter of urban maternity ward closings
Patients, especially in Black and brown communities, have had delivery plans upended and are scrambling for solutions. 17 of the nearly 50 obstetric ward closings…
A presidential debate, GLP-1s for kids, and ultra-processed foods research
Today in health news: Are weight loss drugs safe for kids? Plus, research on ultra-processed foods and their impact on health.
Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries
Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries, a new analysis finds.